1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Maryland >
  6. Mesoblast Acquires Osiris Therapeutics - Mesenchymal Stem Cell Business

M&A Deal Summary

Mesoblast Acquires Osiris Therapeutics - Mesenchymal Stem Cell Business

On October 10, 2013, Mesoblast acquired life science company Osiris Therapeutics - Mesenchymal Stem Cell Business from Osiris Therapeutics

Acquisition Highlights
  • This is Mesoblast’s 2nd transaction in the Life Science sector.
  • This is Mesoblast’s 2nd transaction in the United States.
  • This is Mesoblast’s 1st transaction in Maryland.

M&A Deal Summary
Date 2013-10-10
Target Osiris Therapeutics - Mesenchymal Stem Cell Business
Sector Life Science
Buyer(s) Mesoblast
Sellers(s) Osiris Therapeutics
Deal Type Divestiture

Target

Osiris Therapeutics - Mesenchymal Stem Cell Business

Columbia, Maryland, United States
Osiris Therapeutics's Mesenchymal Stem Cell (MSC) Business is a manufacturer of stem cells.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Mesoblast

Melbourne, Australia
Category Company
Founded 2004
Sector Life Science
Employees81
Revenue 17M USD (2025)
DESCRIPTION

Mesoblast is a biotherapeutics company with proprietary cell-based and protein technologies. Mesoblast’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat major conditions with unmet medical needs. Mesoblast was founded in 2004 and is based in Melbourne, Australia.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 1 of 1
State: Maryland M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2013 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-12-07 Angioblast Systems

New York, New York, United States

Angioblast Systems, Inc. is a biotechnology company. Angioblast is a provider in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases.

Buy -

Seller(S) 1

SELLER

Osiris Therapeutics

Columbia, Maryland, United States
Category Company
Founded 1992
Sector Life Science
Employees211
Revenue 119M USD (2017)
DESCRIPTION

Osiris Therapeutics, Inc. is a stem cell company develops stem cell drug remestemcel-L for graft versus host disease. Osiris Therapeutics was founded in 1992 and is based in Columbia, Maryland.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 2 of 2
State: Maryland M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2013 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-05-08 Osteocel Biologics Business

United States

Osteocel Biologics Business includes a proprietary adult stem cell bone graft product containing beneficial properties similar to autograft, as well as a processing facility with significant supply stream capacity.

Sell -
Mergr

Solution for

Product

Company

Legal